European Commission announced that 8 large-scale research projects, aimed at developing treatments and diagnostics for the coronavirus,were selected in a fast-track call for proposals, launched in March by the Innovative Medicines Initiative (IMI), a public-private partnership.
In order to fund a larger number of high-quality proposals, the Commission increased its commitment to €72 million (up from the originally planned €45 million) from Horizon 2020, the EU’s research and innovation programme. €45 million will be provided by the pharmaceutical industry, IMI associated partners and other organisations involved with the projects, bringing the total investment to €117 million.
The projects selected are part of the common European response to the coronavirus outbreak that the Commission is coordinating since the beginning of the crisis. On 4 May, the Commission pledged €1.4 billion in total during the Coronavirus Global Response pledging event, of which €1 billion comes through Horizon 2020 and is aimed at developing vaccines, new treatments and diagnostic tools to prevent the spread of the coronavirus. Moreover, since January 2020 the Commission has mobilised a total of €352 million under Horizon 2020...
Full text at GMPnews.Net